Topical Immunotherapy in Dermatology

Topical immunotherapy was used since the 1970s to treat skin diseases like extensive alopecia areata and resistant viral warts, believed to result from altered immunological states. Despite its effectiveness, it was offered by only a few dermatology departments in the UK. Diphencyprone (DCP) was preferred over dinitrochlorobenzene (DNCB) and squaric acid dibutyl ester (SADBE) due to its advantages. Careful handling of solutions helped avoid sensitisation of medical staff. Common risks included local blistering and eczematous eruptions, while vitiligo and erythema multiforme-like reactions were rare. DCP under close supervision was a useful treatment option for severe alopecia areata and resistant viral warts.